Cover Image
Read Now

Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)

The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, February 2018
Series:CADTH common drug review clinical review report
Subjects:
Protease Inhibitors / Adverse Effects
Canada
Antiviral Agents / Therapeutic Use
Protease Inhibitors / Therapeutic Use
Hepatitis C, Chronic / Drug Therapy
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults
Physical Description:1 PDF file (112 pages) illustrations

Similar Items